Financière de Tubize SAの資産のリターン
Financière de Tubize SAの資産のリターン は何ですか。
Financière de Tubize SAの資産のリターン は-0.03%です。
資産のリターン の定義は何ですか。
資産のリターンは 、企業の資産が収益を生み出す際の収益性を示します。純利益を平均総資産で除して計算されます。
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
EURONEXTのセクタHealth Careにおける資産のリターン の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の資産のリターン
- Archon Mineralsの資産のリターン は-0.03%です。
- Grainger Plcの資産のリターン は-0.03%です。
- Lakshmi Precision Screwsの資産のリターン は-0.03%です。
- FinTech Acquisition IIIの資産のリターン は-0.03%です。
- FinTech Acquisition IIIの資産のリターン は-0.03%です。
- Gatiの資産のリターン は-0.03%です。
- Financière de Tubize SAの資産のリターン は-0.03%です。
- Seadrill Partnersの資産のリターン は-0.02%です。
- Seadrill Partnersの資産のリターン は-0.02%です。
- KCR Residential REIT plcの資産のリターン は-0.02%です。
- Tyson Foodsの資産のリターン は-0.02%です。
- Gatiの資産のリターン は-0.02%です。
- Financiere Moncey SAの資産のリターン は-0.02%です。